Healthcare Stocks Lag Broader Markets; Prima BioMed Jumps 44% After Cancer Drug Picks Up Regulatory OKs


Shutterstock photo

Top Healthcare Stocks

JNJ +1.68%

PFE +0.62%

ABT +0.83%

MRK +0.49%

AMGN +0.87%

Healthcare stocks finished moderately higher with the NYSE Healthcare Sector Index adding 0.5% and shares of healthcare companies in the S&P 500 climbing 0.6% as a group.

In company news, Australia-based oncology biotechnology firm Prima BioMed ( PBMD ) jumped in U.S. trading Thursday, climbing 44% to finish at $1.68 a share after a protocol update in a study of its epithelial ovarian cancer treatment candidate CAN-004.

The company says multiple jurisdictions have now approved its amended CAN-004 protocol including regulators in Latvia, Lithuania, Bulgaria, Ukraine and Belarus. The CAN-004 trial was approved by the Belgian regulators in January.

The CAN-004 amendment has also been approved by a number of ethics committees and institutional review boards, including sites in the United States, Australia, Belgium, Bulgaria, Latvia, and Lithuania. Prior to enrolling patients into the amended CAN-004 protocol, a positive review is required from the competent regulatory authority and the ethics committee for each site, the company said.

In other sector news,

(-) TEVA, Gives in to profit-taking despite a 5% increase in the drug-maker's quarterly dividend and Q4 results above Street expectations and Q4 results that beat analyst forecasts.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by